Skip to main content
main-content

30-09-2020 | Gastrointestinal cancer | Video

ESMO 2020 | Adjuvant nivolumab potential new standard-of-care for esophageal cancer

Ronan Kelly describes the main findings of the CheckMate 577 trial showing the disease-free survival benefit and tolerability of adjuvant nivolumab in individuals with resected esophageal or gastroesophageal junction cancer (4:34).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits